Table 2.
Bi‐yearly evolution of baseline characteristics
| All drugs | 2009‐10 | 2011‐12 | 2013‐14 | 2015‐16 | |
|---|---|---|---|---|---|
| N (%) | 735 | 66(8.98) | 175 (23.80) | 211 (28.70) | 283 (38.5) |
| Age (±SD) | 59.7 ± 10.5 | 60.9 ± 10.7 | 60.5 ± 10.5 | 59.1 ± 10.3 | 58.9 ± 10.8 |
| Male sex (%) | 50 | 50 | 51 | 46 | 52 |
| DM duration (years ±SD) | 9.01 ± 7.4 | 7.49 ± 5.2 | 8.91 ± 7.7 | 8.90 ± 7.0 | 9.51 ± 7.8* |
| HbA1c (±SD) | 8.18 ± 1.5 | 7.84 ± 1.5 | 8.22 ± 1.7 | 8.01 ± 1.4 | 8.36 ± 1.4* |
| FPG mg/dL (±SD) | 177 ± 59 | 175 ± 61 | 173 ± 60 | 174 ± 54 | 182 ± 62 |
| BMI (±SD) | 38.56 ± 6.6 | 37.72 ± 7.2 | 39.85 ± 6.9 | 38.99 ± 6.4 | 37.60 ± 6.3 |
| Other ADM. N (±SD) | 2.18 ± 0.99 | 1.89 ± 1.0 | 2.03 ± 0.95* | 2.21 ± 0.99* | 2.31 ± 0.99** |
| Metformin (%) | 91.29 | 89.23 | 94.12 | 90.69 | 90.48 |
| SU (%) | 31.46 | 44.62 | 35.88 | 32.84 | 24.54 |
| DPP‐IV‐I (%) | 37.24 | 21.88 | 29.17 | 43.63 | 41.03 |
| Pioglitazone (%) | 1.69 | 3.13 | 2.37 | 1.96 | 0.74 |
| SGLT2‐I (%) | 3.79 | 0.0 | 0.59 | 0.98 | 8.79 |
| Basal insulin (%) | 39.04 | 24.62 | 28.24 | 37.75 | 50.18 |
| Bolus insulin (%) | 18.38 | 13.85 | 17.58 | 18.32 | 20.07 |
| Index drug, n (%) | |||||
| Exenatide bid | 108 (14.69) | 64 (96.92) | 30 (17.14) | 11 (5.21) | 3 (1.06) |
| Lixisenatide | 51 (6.93) | 0 | 0 | 44 (20.85) | 7 (2.47) |
| Liraglutide | 328 (44.62) | 2 (3.08) | 145 (82.85) | 112 (53.08) | 69 (24.38) |
| Exenatide OW | 176 (23.94) | 0 | 0 | 44 (20.85) | 132 (46.64) |
| Dulaglutide | 72 (9.79) | 0 | 0 | 0 | 72 (25.44) |
ADM, antidiabetic medications; BMI, body mass index; DM, diabetes mellitus; DPP‐IV‐I, dipeptidyl peptidase‐IV inhibitor; FPG, fasting plasma glucose; SD, Standard deviation; SGLT2‐I, sodium‐glucose cotransporter‐2 inhibitor; SU, sulfonylurea.
a
P < 0.05.
b
P < 0.01 vs 2009‐10. ANCOVA test for repeated measures.